The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Type 2 Diabetes reveal that agents from the incretin mimetics drug class—dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) analogues—are the most promising drug classes because they improve upon key areas of safety and efficacy. DPP-IV inhibitors such as Januvia have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues such as Bydureon and Byetta combine superior glucose-lowering and weight-loss capabilities and are particularly useful for the significant proportion of type 2 diabetics who are obese. Among all drug classes, DPP-IV inhibitors and GLP-1 analogues will experience the largest upturn in market share, increasing from 12 percent in 2009 to 30 percent in 2019.

"Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position while other DPP-IV inhibitors will struggle, owing to their lack of clinical advantages over Januvia," said Decision Resources Analyst Yannick Maneuf, Ph.D. "GLP-1 analogues have a strong efficacy profile, they elicit weight loss and also have limited safety liabilities and—despite requiring an injection—GLP-1 analogues enjoy great popularity among thought leaders, who see improved glycemia and weight loss in obese type 2 diabetics as landmark progress."

Bydureon, a once-weekly therapy, will earn the most sales in the GLP-1 analogue class, based on its convenience and efficacy. Bydureon and Novo Nordisk's once-daily Victoza will also benefit as a result of the failure of Roche/Ipsen/Teijin/Chugai's taspoglutide, which was the second-most-advanced contender among the long-acting GLP-1 analogues.

The Pharmacor 2010 findings also reveal that although an advisory committee of the U.S. Food and Drug Administration recently agreed to keep GlaxoSmithKline's PPAR-gamma agonist Avandia on the market, the drug will continue to lose sales through 2019 to its main competitor from the same drug class, Takeda's Actos.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED